TriangleTumor-infiltrating Lymphocytes (TIL) (NCT05681780)
Tumor-infiltrating Lymphocytes (TIL) trial for Non Small Cell Lung Cancer (NCT05681780). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
Lo que dice el vídeo
Lee la transcripción
Some lung cancers are driven by one broken gene: EGFR, ALK, ROS1, or HER2. Targeted pills work, for a while. When they stop, immunotherapy rarely helps.
The idea: the few immune cells that did find the tumor are the right ones. Grow them into an army.
Surgeons remove a piece of tumor. In the lab, the T cells inside it are pulled out, sharpened with a signal called CD40 ligand, and multiplied into billions. After chemotherapy clears space, they return by infusion, with nivolumab to keep them switched on.
In Moffitt's earlier lung trial, tumors shrank in eleven of thirteen patients. This trial, led by Ben Creelan, asks whether it is safe in gene-driven cancers. Public record; not medical advice.
¿Ya estás en un ensayo?
Se convierte en un proyecto que hay que manejar: citas, estudios de imagen, análisis, efectos secundarios y papeleo. Triangle lo mantiene organizado en un solo lugar, para ti o para quien te ayuda.
Organizar mi ensayoPrueba gratuita de 7 días, después $9 al mes. Cancela cuando quieras.
Cómo funcionan estos ensayos: qué es de verdad la fase 1 · preguntas frecuentes No es evidencia clínica.